# Pleiotropic Effects of Atorvastatin in High Cardiovascular Risk Patients

> **NCT01013103** · PHASE4 · COMPLETED · sponsor: **Hippocration General Hospital** · enrollment: 72 (actual)

## Conditions studied

- Coronary Artery Disease
- HMG-CoA Reductase Inhibitor Toxicity
- Atherosclerosis
- Oxidative Stress
- Endothelial Dysfunction

## Interventions

- **DRUG:** Atorvastatin, high vs low dose
- **DRUG:** Atorvastatin vs Placebo

## Key facts

- **NCT ID:** NCT01013103
- **Lead sponsor:** Hippocration General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2012-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01013103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01013103, "Pleiotropic Effects of Atorvastatin in High Cardiovascular Risk Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01013103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*